These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 12218722

  • 1. Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate.
    Samsioe G, Li C, Borgfeldt C, Wilawan K, Aberg A, Larsen S.
    Menopause; 2002; 9(5):335-42. PubMed ID: 12218722
    [Abstract] [Full Text] [Related]

  • 2. Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, high-density lipoprotein subfractions and apolipoproteins in postmenopausal women in a two-year, randomized, double-blind, placebo-controlled trial.
    Kotecha PT, Godsland IF, Crook D, Stevenson JC.
    Clin Endocrinol (Oxf); 2020 Apr; 92(4):303-311. PubMed ID: 31925799
    [Abstract] [Full Text] [Related]

  • 3. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O, Lim P, Caubel P.
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [Abstract] [Full Text] [Related]

  • 4. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 May; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 5. Lipoproteins and low-dose estradiol replacement therapy in post-menopausal Type 2 diabetic patients: the effect of addition of norethisterone acetate.
    Owens D, Collins PB, Johnson A, Tomkin GH.
    Diabet Med; 2000 Apr; 17(4):308-15. PubMed ID: 10821298
    [Abstract] [Full Text] [Related]

  • 6. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
    Hemelaar M, Kenemans P, de Bie L, van de Weijer PH, van der Mooren MJ.
    Fertil Steril; 2006 Apr; 85(4):979-88. PubMed ID: 16580384
    [Abstract] [Full Text] [Related]

  • 7. Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women.
    Al-Azzawi F, Wahab M, Sami S, Proudler AJ, Thompson J, Stevenson J.
    Climacteric; 2004 Sep; 7(3):292-300. PubMed ID: 15669554
    [Abstract] [Full Text] [Related]

  • 8. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC.
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [Abstract] [Full Text] [Related]

  • 9. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
    Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, Hirschberger S, Berger M.
    Menopause; 1999 May; 6(1):36-42. PubMed ID: 10100178
    [Abstract] [Full Text] [Related]

  • 10. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
    Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC.
    Arch Intern Med; 2000 Nov 27; 160(21):3315-25. PubMed ID: 11088095
    [Abstract] [Full Text] [Related]

  • 11. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS, Bäckström T, Haeger M, Jonsson B, Bixo M.
    Maturitas; 2004 Jun 15; 48(2):137-46. PubMed ID: 15172088
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
    Nickelsen T, Creatsas G, Rechberger T, Depypere H, Erenus M, Quail D, Arndt T, Bonnar J, Euralox 1 Study Group.
    Climacteric; 2001 Dec 15; 4(4):320-31. PubMed ID: 11770189
    [Abstract] [Full Text] [Related]

  • 13. A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels.
    Spencer C, Crook D, Ross D, Cooper A, Whitehead M, Stevenson J.
    Br J Obstet Gynaecol; 1999 Sep 15; 106(9):948-53. PubMed ID: 10492107
    [Abstract] [Full Text] [Related]

  • 14. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW, Gluck OS, Lang E, Rakov V.
    Menopause; 2005 Sep 15; 12(6):741-8. PubMed ID: 16278618
    [Abstract] [Full Text] [Related]

  • 15. Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women.
    Sendag F, Karadadas N, Ozsener S, Bilgin O.
    Arch Gynecol Obstet; 2002 Jan 15; 266(1):38-43. PubMed ID: 11998963
    [Abstract] [Full Text] [Related]

  • 16. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M, Kahri J, Pyörälä T, Puolakka J, Luotola H, Lappi M, Lahdenperä S, Taskinen MR.
    Atherosclerosis; 1997 Mar 21; 129(2):249-59. PubMed ID: 9105568
    [Abstract] [Full Text] [Related]

  • 17. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J, Hammar M.
    Maturitas; 2005 Apr 11; 50(4):344-52. PubMed ID: 15780536
    [Abstract] [Full Text] [Related]

  • 18. Efficacy on climacteric symptoms of a continuous combined regimen of 1 mg 17beta-estradiol and trimegestone versus two regimens combining 1 or 2 mg 17beta-estradiol and norethisterone acetate.
    Gambacciani M, Spielmann D, Genazzani AR.
    Gynecol Endocrinol; 2005 Aug 11; 21(2):65-73. PubMed ID: 16294457
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
    Saure A, Hirvonen E, Milsom I, Christensen A, Damber MG.
    Maturitas; 1996 May 11; 24(1-2):111-8. PubMed ID: 8794442
    [Abstract] [Full Text] [Related]

  • 20. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial.
    Falkeborn M, Lithell H, Persson I, Vessby B, Naessén T.
    Climacteric; 2002 Sep 11; 5(3):240-8. PubMed ID: 12419082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.